Compounds > prostaglandin-e2-methyl-ester

prostaglandin-e2-methyl-ester and Narcolepsy

prostaglandin-e2-methyl-ester has been researched along with Narcolepsy* in 1 studies

Other Studies

1 other study(ies) available for prostaglandin-e2-methyl-ester and Narcolepsy

Article	Year
Prostaglandin E2 and its methyl ester reduce cataplexy in canine narcolepsy. Proceedings of the National Academy of Sciences of the United States of America, 1989, Volume: 86, Issue:7 The effects of intravenous administration of prostaglandins (PGs) were investigated in genetically narcoleptic Doberman pinschers. The treatment of narcoleptic dogs with PGE2 and PGE2 methyl ester, but not PGD2 and PGD2 methyl ester, induced a dose-dependent reduction of canine cataplexy, a dissociated manifestation of rapid-eye-movement sleep. The effect was specific and not associated with any change in other behavior. Furthermore, the effect was long-lasting (up to 2 hr) and could not be explained by the acute cardiovascular changes seen after intravenous PG administration. PGE2 methyl ester, a lipophilic derivative of PGE2 with more central penetration than PGE2, was 4 times more potent than PGE2. These results indicate that PGE2 modifies cataplexy through a central effect and suggest that this prostaglandin may play a role in rapid-eye-movement sleep regulation. Topics: Animals; Blood Pressure; Body Temperature; Cataplexy; Dinoprostone; Dog Diseases; Dogs; Heart Rate; Motor Activity; Narcolepsy; Reference Values; Sleep	1989

Article

Year

Prostaglandin E2 and its methyl ester reduce cataplexy in canine narcolepsy.

Proceedings of the National Academy of Sciences of the United States of America, 1989, Volume: 86, Issue:7

The effects of intravenous administration of prostaglandins (PGs) were investigated in genetically narcoleptic Doberman pinschers. The treatment of narcoleptic dogs with PGE2 and PGE2 methyl ester, but not PGD2 and PGD2 methyl ester, induced a dose-dependent reduction of canine cataplexy, a dissociated manifestation of rapid-eye-movement sleep. The effect was specific and not associated with any change in other behavior. Furthermore, the effect was long-lasting (up to 2 hr) and could not be explained by the acute cardiovascular changes seen after intravenous PG administration. PGE2 methyl ester, a lipophilic derivative of PGE2 with more central penetration than PGE2, was 4 times more potent than PGE2. These results indicate that PGE2 modifies cataplexy through a central effect and suggest that this prostaglandin may play a role in rapid-eye-movement sleep regulation.

Topics: Animals; Blood Pressure; Body Temperature; Cataplexy; Dinoprostone; Dog Diseases; Dogs; Heart Rate; Motor Activity; Narcolepsy; Reference Values; Sleep

1989